Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Predictable modulation of cancer treatment outcomes by the gut microbiota.

Heshiki Y, Vazquez-Uribe R, Li J, Ni Y, Quainoo S, Imamovic L, Li J, Sørensen M, Chow BKC, Weiss GJ, Xu A, Sommer MOA, Panagiotou G.

Microbiome. 2020 Mar 5;8(1):28. doi: 10.1186/s40168-020-00811-2.

2.

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.

Friedlaender A, Drilon A, Weiss GJ, Banna GL, Addeo A.

Cancer Treat Rev. 2020 Apr;85:101978. doi: 10.1016/j.ctrv.2020.101978. Epub 2020 Feb 7. Review.

PMID:
32062493
3.

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.

Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner RS, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR.

Clin Cancer Res. 2020 Mar 1;26(5):1025-1033. doi: 10.1158/1078-0432.CCR-19-2609. Epub 2019 Dec 3.

4.

Lack of accountability in upholding authorship standards in prominent medical oncology clinical trials.

Gui DY, Weiss GJ.

Curr Oncol. 2019 Oct;26(5):e693-e695. doi: 10.3747/co.26.4789. Epub 2019 Oct 1.

5.

Tumor Mutation Burden-From Doubts to Concerns-In Reply.

Addeo A, Banna GL, Weiss GJ.

JAMA Oncol. 2019 Oct 24. doi: 10.1001/jamaoncol.2019.4141. [Epub ahead of print] No abstract available.

PMID:
31647493
6.

Measuring tumor mutation burden in cell-free DNA: advantages and limits.

Addeo A, Weiss GJ.

Transl Lung Cancer Res. 2019 Aug;8(4):553-555. doi: 10.21037/tlcr.2019.03.04. No abstract available.

7.

Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC).

Lohinai Z, Megyesfalvi Z, Dome B, Weiss GJ.

Transl Oncol. 2019 Dec;12(12):1539-1548. doi: 10.1016/j.tranon.2019.08.004. Epub 2019 Aug 31.

8.

Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer.

Lohinai Z, Bonanno L, Aksarin A, Pavan A, Megyesfalvi Z, Santa B, Hollosi V, Hegedus B, Moldvay J, Conte P, Ter-Ovanesov M, Bilan E, Dome B, Weiss GJ.

PeerJ. 2019 Jul 29;7:e7232. doi: 10.7717/peerj.7232. eCollection 2019.

9.

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.

Lin CC, Arkenau HT, Lu S, Sachdev J, de Castro Carpeño J, Mita M, Dziadziuszko R, Su WC, Bobilev D, Hughes L, Chan J, Zhang ZY, Weiss GJ.

Br J Cancer. 2019 Jul;121(2):131-138. doi: 10.1038/s41416-019-0503-9. Epub 2019 Jun 20.

10.

Tumor Mutation Burden-From Hopes to Doubts.

Addeo A, Banna GL, Weiss GJ.

JAMA Oncol. 2019 Jul 1;5(7):934-935. doi: 10.1001/jamaoncol.2019.0626. No abstract available.

PMID:
31145420
11.

Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.

Addeo A, Weiss GJ, Gyawali B.

JAMA Netw Open. 2019 May 3;2(5):e193684. doi: 10.1001/jamanetworkopen.2019.3684. Review.

12.

Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.

Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V.

Invest New Drugs. 2019 Aug;37(4):797. doi: 10.1007/s10637-019-00763-x.

PMID:
31020607
13.

Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.

Weiss GJ, Addeo A.

N Engl J Med. 2019 Feb 28;380(9):888-889. doi: 10.1056/NEJMc1900123. No abstract available.

PMID:
30811920
14.

Discordant financial conflicts of interest disclosures between clinical trial conference abstract and subsequent publication.

Weiss GJ, Davis RB.

PeerJ. 2019 Feb 11;7:e6423. doi: 10.7717/peerj.6423. eCollection 2019.

15.

A new era of treating advanced lung cancer is upon us.

Weiss GJ.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S202-S205. doi: 10.21037/tlcr.2018.07.03. No abstract available.

16.

Correction: Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.

Morris SM, Subramanian J, Gel ES, Runger GC, Thompson EJ, Mallery DW, Weiss GJ.

PLoS One. 2018 Jun 28;13(6):e0200224. doi: 10.1371/journal.pone.0200224. eCollection 2018.

17.

Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.

Morris SM, Subramanian J, Gel ES, Runger GC, Thompson EJ, Mallery DW, Weiss GJ.

PLoS One. 2018 Apr 27;13(4):e0196556. doi: 10.1371/journal.pone.0196556. eCollection 2018. Erratum in: PLoS One. 2018 Jun 28;13(6):e0200224.

18.

Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.

Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW.

Int J Cancer. 2018 Jun 1;142(11):2355-2362. doi: 10.1002/ijc.31245. Epub 2018 Jan 30.

19.

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.

Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT.

J Gastrointest Oncol. 2017 Dec;8(6):925-935. doi: 10.21037/jgo.2017.09.05.

20.
21.

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.

Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V.

Invest New Drugs. 2018 Feb;36(1):96-102. doi: 10.1007/s10637-017-0525-1. Epub 2017 Nov 8. Erratum in: Invest New Drugs. 2019 Aug;37(4):797.

PMID:
29119276
22.

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.

Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D.

Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20.

23.

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort.

Burris HA, Bakewell S, Bendell JC, Infante J, Jones SF, Spigel DR, Weiss GJ, Ramanathan RK, Ogden A, Von Hoff D.

ESMO Open. 2017 Feb 23;1(6):e000154. doi: 10.1136/esmoopen-2016-000154. eCollection 2016.

24.

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK.

Invest New Drugs. 2018 Feb;36(1):85-95. doi: 10.1007/s10637-017-0491-7. Epub 2017 Jul 20.

PMID:
28726132
25.

Prophylactic cranial irradiation in small-cell lung cancer.

Weiss GJ, Lohinai Z.

Lancet Oncol. 2017 Jul;18(7):e367. doi: 10.1016/S1470-2045(17)30405-9. No abstract available.

PMID:
28677570
26.

A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).

Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V.

Br J Cancer. 2017 Jun 27;117(1):33-40. doi: 10.1038/bjc.2017.145. Epub 2017 Jun 6.

27.

A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.

Weiss GJ, Byron SA, Aldrich J, Sangal A, Barilla H, Kiefer JA, Carpten JD, Craig DW, Whitsett TG.

PLoS One. 2017 Jun 6;12(6):e0179170. doi: 10.1371/journal.pone.0179170. eCollection 2017.

28.

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC.

Br J Cancer. 2017 Jun 6;116(12):1505-1512. doi: 10.1038/bjc.2017.92. Epub 2017 May 2.

29.

Using circulating cell-free DNA to monitor personalized cancer therapy.

Oellerich M, Schütz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, Walson PD.

Crit Rev Clin Lab Sci. 2017 May;54(3):205-218. doi: 10.1080/10408363.2017.1299683. Epub 2017 Apr 10. Review.

PMID:
28393575
30.

Reviewing concomitant medications for participants in oncology clinical trials.

McGahey KE, Weiss GJ.

Am J Health Syst Pharm. 2017 Apr 15;74(8):580-586. doi: 10.2146/ajhp151052.

PMID:
28389457
31.

Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, Barilla H, Cubello R, Quan W Jr, Sangal A, Khemka V, Waypa J, Mitchell WM, Urnovitz H, Schütz E.

Clin Cancer Res. 2017 Sep 1;23(17):5074-5081. doi: 10.1158/1078-0432.CCR-17-0231. Epub 2017 Mar 20.

32.

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).

Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ.

Invest New Drugs. 2017 Oct;35(5):608-615. doi: 10.1007/s10637-017-0441-4. Epub 2017 Feb 16.

33.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR.

Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.

PMID:
27836716
34.

Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'.

Markman M, Kramer K, Alvarez RH, Weiss GJ, Ahn E, Daneker GW.

Oncology. 2016;91(6):299-301. Epub 2016 Oct 6. Review.

PMID:
27705967
35.

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.

Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.

36.

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.

Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA 3rd, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC.

Clin Cancer Res. 2016 Jul 1;22(13):3157-63. doi: 10.1158/1078-0432.CCR-15-2548. Epub 2016 Feb 4.

37.

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC).

Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ.

PLoS One. 2016 Jan 6;11(1):e0144797. doi: 10.1371/journal.pone.0144797. eCollection 2016.

38.

Precision medicine: lessons learned from the SHIVA trial.

Weiss GJ.

Lancet Oncol. 2015 Dec;16(16):e580. doi: 10.1016/S1470-2045(15)00387-3. No abstract available.

PMID:
26678199
39.

Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.

Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg BJ, Mao Y, Barington L, Pereira MA, LoBello J, Endo M, Fazli L, Soden J, Wang CK, Sander AF, Dagil R, Thrane S, Holst PJ, Meng L, Favero F, Weiss GJ, Nielsen MA, Freeth J, Nielsen TO, Zaia J, Tran NL, Trent J, Babcook JS, Theander TG, Sorensen PH, Daugaard M.

Cancer Cell. 2015 Oct 12;28(4):500-514. doi: 10.1016/j.ccell.2015.09.003.

40.

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.

Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK.

Clin Cancer Res. 2016 Feb 15;22(4):827-36. doi: 10.1158/1078-0432.CCR-15-0431. Epub 2015 Oct 7.

41.

Comparing two assays for clinical genomic profiling: the devil is in the data [Letter of clarification].

Weiss GJ, Khemka V.

Onco Targets Ther. 2015 Sep 18;8:2643. doi: 10.2147/OTT.S96038. eCollection 2015. No abstract available.

42.

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD.

Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30.

43.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G.

N Engl J Med. 2015 Jul 30;373(5):428-37. doi: 10.1056/NEJMoa1411366.

44.

Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.

Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, Agrawal M, Nichols G, Middleton S, Beryozkina A, Sarapa N, Peck R, Zhi J.

Cancer Chemother Pharmacol. 2015 Sep;76(3):587-95. doi: 10.1007/s00280-015-2830-8. Epub 2015 Jul 26.

PMID:
26210682
45.

Influence of Robotic-Assisted Surgery on Readmission Burden.

Weiss GJ.

J Clin Oncol. 2015 Jul 1;33(19):2229. doi: 10.1200/JCO.2015.61.7464. Epub 2015 May 26. No abstract available.

PMID:
26014299
46.

Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making.

Weiss GJ, Hoff BR, Whitehead RP, Sangal A, Gingrich SA, Penny RJ, Mallery DW, Morris SM, Thompson EJ, Loesch DM, Khemka V.

Onco Targets Ther. 2015 Apr 24;8:959-67. doi: 10.2147/OTT.S81995. eCollection 2015.

47.

Translating next-generation sequencing from clinical trials to clinical practice for the treatment of advanced cancers.

Dearing KR, Weiss GJ.

Per Med. 2015 Mar;12(2):155-162. doi: 10.2217/pme.14.54. Epub 2015 Jan 20.

PMID:
29754537
48.

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

Infante JR, Weiss GJ, Jones S, Tibes R, Bauer TM, Bendell JC, Hinson JM Jr, Von Hoff DD, Burris HA 3rd, Orlemans EO, Ramanathan RK.

Eur J Cancer. 2014 Nov;50(17):2897-904. doi: 10.1016/j.ejca.2014.07.017. Epub 2014 Sep 25.

PMID:
25262379
49.

Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic.

Weiss GJ, Ganeshan B, Miles KA, Campbell DH, Cheung PY, Frank S, Korn RL.

PLoS One. 2014 Jul 2;9(7):e100244. doi: 10.1371/journal.pone.0100244. eCollection 2014.

50.

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK.

Br J Cancer. 2014 Jul 15;111(2):272-80. doi: 10.1038/bjc.2014.290. Epub 2014 Jun 5.

Supplemental Content

Loading ...
Support Center